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ABSTRACT 
There is some published evidence which suggests that the clinical outcomes and pathogens associated with 
Acute Pyelonephritis (AP) differ between diabetics and non-diabetics. However, current guidelines do not 
make treatment distinctions based on Diabetes Mellitus (DM) status. The objectives of this study were to 
identify  the  microbiological  and  clinical  characteristics  of  hospitalized  patients  with  AP  and  investigate 
differences between patients with and without DM. A retrospective cohort study of adult patients admitted 
with  AP  at  The  Brooklyn  Hospital  Center  was  conducted.  Patient  information  was  accessed  through  the 
hospital’s electronic medical record system and patients were identified through primary discharge diagnosis 
ICD-9 codes for AP within the past three years. Patients were then screened for DM; all DM patients were 
randomly matched in a 2:1 manner to patients without DM admitted with AP during the same time period. A 
total of 48 patients were included in this analysis, 16 with DM and 32 without DM. There was a significantly 
greater median length of stay among diabetics (6 (3-8) Vs. 3 days (2-5), P = 0.02). There was a greater rate of 
antimicrobial  resistance  among  DM  patients,  with  a  significantly  greater  rate  of  infection  by  Multi-Drug 
Resistant Organisms (MDRO) (4/16 [25%] Vs. 1/32 [3%], P = 0.036). Escherichia coli was the overall most 
common uropathogen, in 50% of the DM patients and 53% of the non-DM patients. Ceftriaxone monotherapy 
was the most commonly used empiric regimen in both groups (10/16 [63%] Vs. 19/32 [59%]) and there were 
similar rates of ceftriaxone sensitivity (8/10 [80%] Vs. 19/19 [100%]). Patients with DM were at greater risk of 
infection  from  MDRO  and  required  longer  lengths  of  hospitalization  than  patients  without  DM.  Further 
investigation is warranted to guide effective empiric treatment of AP among patients with DM. 
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1. INTRODUCTION 
Patients  with  Diabetes  Mellitus  (DM)  have  been 
found to be at an increased risk of developing Urinary 
Tract  Infections  (UTI)  (Patterson  and  Andriole,  1997; 
Hirji  et  al.,  2012;  Muller  et  al.,  2005;  Scholes  et  al., 
2005).  The  etiology  of  this  increased  risk  is  multi-
factorial  and  includes  incomplete  bladder  emptying 
secondary  to  autonomic  neuropathy  and  high  urinary 
glucose concentration; both of which promote microbial 
growth (Ronald and Ludwig, 2001). For these reasons, 
patients with DM are known to have an increased rate of 
recurrent  UTIs  (Patterson  and  Andriole,  1997). 
Additionally, severe complications such as emphysematous 
pyelonephritis  and  abscess  formation  may  occur  more 
commonly in patients with DM (Joshi et al., 1999).  
The  microbiological  patterns  of  UTIs  may  differ 
between patients with DM and those without DM. While 
Escherichia  coli  is  the  causative  pathogen  for  the 
majority  of  UTIs  (Saeed  and  Mohammed,  2010), 
Klebsiella spp., Streptococcus spp. and Candida spp. are 
also  common  uropathogens  among  diabetic  patients 
(Kofteridis et al., 2009; Horcajada et al., 2003). Patients 
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Multi-Drug  Resistant  Organisms  (MDRO),  however 
few trials have assessed microbiological differences in 
uropathogens  between  DM  and  non-DM  patients  and 
further  investigation  is  necessary  (Kofteridis  et  al., 
2009; Horcajada et al., 2003). While it is known that 
patients with DM disproportionately suffer from more 
frequent and severe UTIs, current treatment guidelines 
do  not  distinguish  treatment  recommendations  for 
patients with DM and those without DM (Gupta et al., 
2011;  Kofteridis  et  al.,  2009).  The  Infectious  Disease 
Society  of  America  and  The  European  Society  for 
Microbiology  practice  guidelines  for  the  treatment  of 
hospitalized  patients  with  AP  recommend  empiric 
regimens including a fluoroquinolone or aminoglycoside 
with  or  without  ampicillin,  an  extended  spectrum 
penicillin  or  cephalosporin  with  or  without  an 
aminoglycoside, or a carbapenem (Gupta et al., 2011). In 
practice, clinicians often turn to consensus guidelines for 
assistance  with  antibiotic  selection,  however  these 
guidelines  do  not  provide  recommendations  for  the 
optimal management of AP in diabetic patients. The wide 
range  of  antibiotic  recommendations  complicates 
treatment selection and further heightens the need for the 
reevaluation  of  evidence  supporting  empiric  treatment. 
Additionally,  it  is  unknown  what  degree  of  glycemic 
control  can  mitigate  the  risk  of  developing  a  UTI  and 
further complications. Better understanding of clinical and 
microbiological  characteristics  in  this  patient  population 
will help clinicians manage AP. 
In this study, we sought to investigate differences 
based on DM status in the setting of AP. Our primary 
objectives  were  to  evaluate  the  clinical  and 
microbiological characteristics of AP among hospitalized 
patients.  We  hypothesized  that  among  hospitalized 
patients with AP, those with DM may be at a greater 
risk of infection by MDRO and suffer worse clinical 
outcomes  than  those  patients  without  DM.  Our 
secondary objective  was to investigate potential risk 
factors for developing infection by MDROs and assess 
differences based on DM status. The implications of 
these  findings  may  be  important  to  guide  treatment 
recommendations for DM patients with AP. 
2. MATERIALS AND METHODS 
2.1. Study Design and Patient Population  
A  retrospective  cohort  study  was  conducted  of 
patients with and without DM diagnosed with AP and 
admitted between January 2010 and August 2012 to The 
Brooklyn  Hospital  Center,  a  463-bed  community 
teaching  hospital  in  Brooklyn,  NY.  Patients  were 
identified using ICD-9 codes for AP. The study protocol 
was  approved  by  the  hospital’s  institutional  review 
board. Inclusion criteria: (1) Adult patients ≥18 years (2) 
Patients  with  AP  as  primary  discharge  diagnosis  for 
hospitalization.  If  a  patient  was  admitted  for  AP  on 
multiple occasions within the study period, only the first 
episode of infection was included. Exclusion criteria: (1) 
patients with indwelling urinary devices. We randomly 
matched  all  identified  patients  with  DM  to  non-DM 
patients  in  a  2:1  manner;  all  non-DM  patients  were 
admitted for AP during the same time period. 
2.2. Data Collection and Study Definitions  
The  medical  and  laboratory  records  of  eligible 
patients  were  retrospectively  reviewed  for  pertinent 
demographic, laboratory and clinical data. A structured 
data collection form  was used to record the abstracted 
data and all data were compiled into a single database 
using  Microsoft  Access  (Microsoft  Corp,  Redmond, 
Wash). Demographic data included age, gender, place of 
residence prior to hospitalization (home, or transferred 
from an outside hospital or facility), admission to ICU, 
total  length  of  stay,  length  of  stay  after  isolation  of 
organism and co-morbid conditions. 
Infections  were  defined  according  to  criteria 
established  by  the  Centers  for  Disease  Control  and 
Prevention  (Horan  et  al.,  2008).  AP  infection  was 
confirmed  based  on  clinical  signs  and  symptoms  of 
infection and we considered the AP diagnosis accurate if 
patients  had  fever  (>38  C),  flank  pain,  or  flank 
tenderness  associated  with  pyuria  (>10  WBC  mL
-1). 
Then, patients were screened for DM by assessing the 
past medical history for DM. Diagnosis of DM was made 
based  on  American  Diabetes  Association  criteria,  Hb 
A1c ≥6.5%, fasting plasma glucose ≥126 mg dL
-1, 2 h 
plasma  glucose  ≥200  mg  dL
-1  during  an  oral  glucose 
tolerance  test,  or  a  random  glucose  level  of  ≥200  mg 
dL
-1 with symptoms of hyperglycemia (ADA, 2013).  
Time  to  achieve  clinical  stability  was  defined  as 
return of altered mental status and abnormal vital signs 
to normal baseline values (heart rate ≤100 beats min
-1, 
systolic blood pressure ≥90 mm Hg, respiratory rate ≤24 
min
-1, oxygen saturation ≥90% and temperature ≤37.2°C 
[99°F]).  Response  included  complete  and  partial 
responses.  A  complete  response  was  defined  as 
resolution  of  fever,  leukocytosis  and  local  signs  of 
infections; a partial response was improvement of some 
but  not all of  these conditions.  Non-response included 
failure,  relapse  and  death.  Failure  was  defined  as  no 
improvement  or  worsening  of  signs  and  symptoms  of 
infections; relapse was recurrence of infection with the 
same  organism  at  anybody  site  within  1  month  after 
discontinuation of therapy. Kathleen Lynch et al. / American Journal of Infectious Diseases 10 (2): 71-76, 2014 
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Risk  factors  for  MDRO  were  defined  according  to 
criteria  described  by  clinical  practice  guideline  (ATS, 
2005).  Uropathogens  were  deemed  to  be  MDRO  if 
resistant to two or more classes of antibiotics. 
2.3. Outcome Analysis 
Primary  outcomes  measures  were  clinical  and 
microbiological  characteristics.  The  clinical  outcomes 
assessed were length of stay, rate of complications and 
time  to  clinical  stability.  The  microbiological 
characteristics assessed were uropathogen identified and 
drug susceptibilities. Standard microbiological methods 
were used to identify isolates; the Vitek 2 automated 
system (BioMe´rieux) was used to determine is olate 
susceptibilities.  Our  secondary  outcome  was  to 
identify  risk  factors  for  developing  infection  by 
MDROs.  For  both  outcomes  analysis,  patients  were 
compared by DM diagnosis. 
2.4. Statistical Analysis  
GraphPad Prism, version 6.0 (GraphPad Software, 
Inc., San Diego, Calif), was used to perform statistical 
analyses. The cohort group variables were compared 
using  the  t  test,  Mann-Whitney  U  test,  χ
2  test,  or 
Fisher  exact  test  where  applicable.  All  statistical  tests 
were 2-tailed; p≤0.05 denotes statistical significance. 
3. RESULTS 
As this study was retrospective our sample size was 
predetermined. During our study period, there were 156 
patients  with  AP.  Of  these,  we  excluded  15  pediatric 
patients  less  than  18  years  old  and  8  patients  with 
indwelling urinary devices. We included in our study 16 
patients with DM and we matched these patients in a 2:1 
manner with 32 randomly selected patients without DM 
for comparison of the clinical and microbiological course 
of AP between these 2 groups. 
Table 1 shows the demographic characteristics of our 
sample.  The  median  age  of  DM  patients  was 
significantly greater than non-DM patients (49 [37-62] 
Vs. 27 [23-39], P = 0.006). The overwhelming majority 
of patients in both groups were female. DM patients had 
greater BMIs than non-DM patients however; this was 
not statistically significant different (30 [24-36] Vs. 26 
[24-28], P = 0.18). We were only able to assess long-
term glycemic control in the DM group, as we did not 
have HbA1C values for patients without DM. All but one 
diabetic patient had a HbA1C level collected during the 
AP admission or within three months earlier; the median 
HbA1C  was  elevated  at  8.7,  therefore,  this  group  had 
very poor glycemic control. 
We next assessed the clinical outcomes of this sample 
(Table 2). We found that days until clinical stability was 
similar between the two groups, with a median of one 
day  for  both  groups.  There  was  a  trend  towards  an 
increase in complications among the DM group but this 
did not achieve statistical significance (5/16 [31%] Vs. 
3/32 [9.4%], P = 0.13). The most common complication 
was bacteremia. Diabetic patients were found to require 
longer LOS when compare to non-diabetics (6 days [3-8] 
vs.  3  days  [2-5],  P  =  0.02).  Lastly,  we  analyzed  final 
response at discharge. We found that 25% (12/48) of our 
sample and within each group had a complete response 
at  discharge  and  75%  (36/48)  had  a  partial  response 
meaning  they  showed  some  clinical  improvement  but 
were either discharged with antibiotics or had some signs 
or symptoms of infection at discharge.  
As shown in Table 3, we analyzed microbiological 
differences between patients with DM and those without. 
We  found  that  for  both  populations,  E.  coli  was  the 
primary  uropathogen  identified.  We  found  that  among 
these  E.  coli  isolates,  those  from  DM  patients  were 
significantly more likely to have antimicrobial resistance 
to ampicillin (100% [8/8] Vs 24% [4/17], P = 0.002) and 
levofloxacin (63% [5/8] Vs. 6% [1/17], P = 0.009) but 
there were similar rates of resistance to sulfamethoxazole 
trimethoprim (50% [4/8] Vs. 12% [2/17], P = 0.11) and 
there  was  one  patient  in  each  group  with  Extended 
Spectrum  Beta  Lactamase  (ESBL)  producing  E.  coli. 
There were similar rates of infection from Klebsiella sp. 
(6% [1/16] Vs 6% [2/32], P = 0.5) and Enterococcus sp. 
(13% [2/16] Vs. 3% [1/32], P = 0.24) between the two 
groups.  Although  there  was  greater  antimicrobial 
resistance among the E. coli isolates from DM patients, 
the rates of resistance to the empiric regimen selected by 
clinicians  was  similar  between  the  two  groups  (19% 
[3/16]  Vs  3%  [1/32],  P  =  0.096).  The  most  common 
empiric regimen was ceftriaxone, which the majority of 
uropathogens were susceptible.  
 Table  4  shows  risk  factors  for  MDRO  and  active 
infection, 25% (12/48) of our sample had at least one 
risk factor including immunosuppression, antibiotics or 
hospitalization >2 days in the past 90 days, or nursing 
home residence. There was a greater rate of patients with 
risk factors in the DM group but this was not statistically 
significantly different, (38% [6/16] Vs 19% [6/32] P = 
0.178). Although there was no difference in risk factors 
for MDRO infection, we found that AP infection by an 
MDRO was significantly greater in the DM group (25% 
[4/16]  Vs  3%  [1/32],  P  =  0.036).Kathleen Lynch et al. / American Journal of Infectious Diseases 10 (2): 71-76, 2014 
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Table 1. Patient demographics 
Age, years   Overall N = 48   With DM N = 16   Without DM N = 32   P-value 
Median (IQR)   35 (23-47)   49 (37-62)   27 (23-39)   0.006 
Male gender, n (%)   2 (4)   1 (6)   1 (3)   0.61 
BMI, median (IQR)   26 (23-30)   30 (24-36)   26 (24-28)   0.18 
HbA1c, median (IQR)   N/A   8.7 (7.2-12)   N/A   N/A 
Nursing home residence, n (%)   1 (2)   0   1 (3)   0.12 
 
Table 2. Clinical characteristics and outcomes 
  Overall N = 48   With DM N = 16   Without DM N = 32   P-value  
Time to clinical stability (days), median (IQR)   1   1 (1-3)   1 (1-2)   0.13 
Complications, n (%)   8 (17)  5 (31)  3 (9.4)  0.13 
Bacteremia   6  3  3 
Abscess formation   1  1  0 
Emphysematous pyelonephritis   1   1   0 
Length of stay, median (IQR)   4 (2-6)   6 (3-8)   3 (2-5)   0.02 
Final response, n (%)   12 (25)  4 (25)  8 (25)  1.00 
Complete partial   36 (75)   12 (75)   24 (75)   1.00 
 
Table 3. Microbiological characteristics 
  Overall   With DM   Without DM 
  N = 48 (%)  N = 16 (%)  N = 32 (%)  P-value 
Escherichia coli   25 (52)  8 (50)  17 (53)  0.830 
Resistant to Ampicillin   12 (48)   8 (100)   4 (24)  0.002 
Resistant to TMP-SMX   6 (24)  4 (50)  2 (12)  0.110 
Resistant to Levofloxacin   6 (24)  5 (63)  1 (6)  0.009 
ESBL +    2 (8)  1 (12)  1 (6)  1.000 
Klebsiella spp.   3 (6)  1 (6)  2 (6)  0.500 
ESBL +   1 (33)   1   0   0.200 
Enterococcus spp.   3 (6)  2 (13)  1 (3)  0.240 
VRE   1 (33)   1 (50)   0   0.200 
Ceftriaxone empiric monotherapy   29 (60)  10 (63)  19 (59)  1.000 
Sensitive to ceftriaxone   27 (93)  8 (80)  19 (100)  10.110 
Uropathogen resistant to empiric regimen  4 (8)   3 (19)  1 (3)  0.096 
 
Table 4. MDRO risk factors 
  Overall   With DM  Without DM 
  N = 48 (%)   N = 16 (%)   N = 32 (%)  P-value 
MDRO Risk Factor   12(25)  6 (38)  6 (19)  0.178 
Immunosuppression   3 (6)  2 (12)  1 (3)  1.000 
Antibiotics in prior 90 days   5 (10)  2 (12)  3 (9)  1.000 
Hospitalization >2 days in past 90 days   4 (8)  2 (12)  2 (6)  1.000 
Nursing home residence   1 (2)   1 (6)   0   1.000 
Infection by MDRO   5 (10)  4 (25)   1 (3)   0.036 
ESBL + E. coli   2 (42)   1 (6)   1 (3)   1.000 
ESBL + Klebsiella spp.   1 (21)   1 (6)   0   1.000 
VRE   1 (21)  1 (6)   0   1.000 
MRSE   1 (21)  1 (6)  0  1.000 
 
4. DISCUSSION 
This study assessed the impact of DM status on the 
course  of  AP  among  hospitalized  patients.  In  this 
sample of patients, we found that those with DM had a 
longer  LOS,  however  other  clinical  outcomes  were 
similar including time to clinical stability and rates of 
complications.  As  for  microbiological  outcomes, 
uropathogen  antimicrobial  resistance  was  greater  in 
patients  with  DM;  however,  empiric  regimen Kathleen Lynch et al. / American Journal of Infectious Diseases 10 (2): 71-76, 2014 
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susceptibility  was  similar  between  the  two  groups 
with  ceftriaxone  being  the  most  common  empiric 
regimen.  This  study  provides  evidence  of 
microbiological differences between patients with DM 
and those without DM as we observed increased rates 
of  uropathogen  resistance  among  DM  patients 
compared to non-DM patients. 
This  is  the  first  trial  to  date  to  investigate  AP 
differences by DM status across a general population 
of  adult  patients.  To  our  knowledge,  the  only  other 
study to investigate these differences was limited to 
elderly  patients  hospitalized  with  AP  in  Greece 
(Kofteridis et al., 2009). Kofteridis et al. (2009) found 
that  DM  patients  had  a  greater  rate  of  bacteremia, 
increased  LOS  and  increased  mortality  compared  to 
elderly  patients  without  DM  while  microbiological 
outcomes  were  similar  between  groups.  In  contrast, 
our  trial  found  that  the  clinical  course  of  AP  was 
similar between the groups but there were significant 
differences  in  microbiological  patterns  of  AP 
infection. This may be due to the fact the population 
in our study cohort were relatively young and healthy 
and  therefore  less  susceptible  to  complications  and 
mortality  from  AP.  As  for  microbiological 
differences,  (Kofteridis  et  al.,  2009)  found  in  their 
study that almost 30% of their patients with DM had 
negative  urine  cultures  likely  due  to  the  common 
practice of self medicating with antibiotics available as 
over the counter medications in Greece. Therefore, they 
could  not  accurately  draw  conclusions  on 
microbiological differences as such a large portion of the 
sample  did  not  have  a  uropathogen  identified.  In  our 
sample,  we  found  that  E.  coli  was  the  most  common 
uropathogen in both groups but there was significantly 
greater  antimicrobial  resistance  observed  among  those 
with  DM.  Despite  these  differences  in  antimicrobial 
resistance,  there  were  similar  rates  of  isolate 
susceptibility  to  the  empiric  regimen  with  ceftriaxone 
monotherapy  the  most  commonly  used.  While  these 
differences  in  antimicrobial  resistance  did  not  affect 
empiric  treatment  at  our  institution,  it  may  vary  by 
institution and local antibiotic resistance patterns. 
There are some potential limitations of this study. 
Our analysis included only 48 patients admitted with 
AP over a period of 3 years. This small sample size 
may not be representative of the overall population of 
patients  admitted  for  AP,  however,  the  size  of  this 
sample  is  similar  to  other  studies  investigating  AP 
(Kofteridis et al., 2009; Horcajada et al., 2003). Since 
this  was  a  retrospective  study,  we  had  to  rely  on 
information  documented  in  the  patient’s  medical 
record, which may be inaccurate or incomplete. 
5. CONCLUSION 
In  conclusion,  we  found  among  this  sample  of 
patients hospitalized with AP, those with DM required 
longer  hospital  lengths  of  stay  and  were  more 
susceptible  to  infection  from  MDROs.  Potential 
limitations include this study’s small sample size and 
retrospective  design.  Further  study  is  warranted  to 
replicate these findings as well as assess the impact of 
glycemic  control  since  those  with  uncontrolled  DM 
may be at a greater risk of infection by MDRO and 
suffer  worse  clinical  outcomes  than  those  patients 
with controlled DM. 
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